# A Single-arm, Exploratory Clinical Study Evaluating the Efficacy and Safety of Bevacizumab in Combination With Anlotinib and Etoposide as First-line Therapy for Elderly Patients With Small-cell Lung Cancer or Those Who Are Intolerant to Intensive Chemotherapy

> **NCT07728955** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University** · enrollment: 64 (estimated)

## Conditions studied

- Small Cell Lung Cancer ( SCLC )

## Interventions

- **DRUG:** benmelstobart in combination with anlotinib and etoposide

## Key facts

- **NCT ID:** NCT07728955
- **Lead sponsor:** Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08-01
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-08-31
- **Target enrollment:** 64 (ESTIMATED)
- **Last updated:** 2026-07-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07728955

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07728955, "A Single-arm, Exploratory Clinical Study Evaluating the Efficacy and Safety of Bevacizumab in Combination With Anlotinib and Etoposide as First-line Therapy for Elderly Patients With Small-cell Lung Cancer or Those Who Are Intolerant to Intensive Chemotherapy". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07728955. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*